DK3464292T3 - Modulatorer af beta-3-adrenerg receptor, der kan anvendes til behandling eller forebyggelse af lidelser relateret dertil - Google Patents
Modulatorer af beta-3-adrenerg receptor, der kan anvendes til behandling eller forebyggelse af lidelser relateret dertil Download PDFInfo
- Publication number
- DK3464292T3 DK3464292T3 DK17730638.8T DK17730638T DK3464292T3 DK 3464292 T3 DK3464292 T3 DK 3464292T3 DK 17730638 T DK17730638 T DK 17730638T DK 3464292 T3 DK3464292 T3 DK 3464292T3
- Authority
- DK
- Denmark
- Prior art keywords
- beta
- prevention
- treatment
- adrenergic receptor
- receptor modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346293P | 2016-06-06 | 2016-06-06 | |
| PCT/US2017/035867 WO2017214002A1 (en) | 2016-06-06 | 2017-06-05 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3464292T3 true DK3464292T3 (da) | 2022-10-31 |
Family
ID=59067920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17730638.8T DK3464292T3 (da) | 2016-06-06 | 2017-06-05 | Modulatorer af beta-3-adrenerg receptor, der kan anvendes til behandling eller forebyggelse af lidelser relateret dertil |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US20190284200A1 (da) |
| EP (1) | EP3464292B8 (da) |
| JP (3) | JP6771246B2 (da) |
| KR (2) | KR102408272B1 (da) |
| CN (1) | CN109563103B (da) |
| AR (1) | AR108772A1 (da) |
| AU (2) | AU2017278102B2 (da) |
| BR (1) | BR112018075201A2 (da) |
| CA (1) | CA3026024A1 (da) |
| CL (1) | CL2018003451A1 (da) |
| CO (1) | CO2019000041A2 (da) |
| CR (1) | CR20180595A (da) |
| DK (1) | DK3464292T3 (da) |
| EA (1) | EA201892817A1 (da) |
| EC (1) | ECSP19001018A (da) |
| ES (1) | ES2929737T3 (da) |
| IL (2) | IL289378B (da) |
| MA (2) | MA44037B1 (da) |
| MX (2) | MX2018015124A (da) |
| MY (1) | MY195982A (da) |
| NI (1) | NI201800130A (da) |
| NZ (1) | NZ749202A (da) |
| PE (1) | PE20190445A1 (da) |
| PH (1) | PH12018502550A1 (da) |
| PT (1) | PT3464292T (da) |
| SG (1) | SG11201810788QA (da) |
| TN (1) | TN2018000391A1 (da) |
| TW (2) | TWI752963B (da) |
| UA (1) | UA125120C2 (da) |
| WO (1) | WO2017214002A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44037B1 (fr) * | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| TW202244048A (zh) | 2017-03-20 | 2022-11-16 | 美商佛瑪治療公司 | 作為丙酮酸激酶（ｐｋｒ）活化劑之吡咯并吡咯組成物 |
| EP3720858B1 (en) | 2017-12-06 | 2023-06-07 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto |
| US20230055923A1 (en) | 2018-09-19 | 2023-02-23 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| BR112021005188A2 (pt) | 2018-09-19 | 2021-06-08 | Forma Therapeutics, Inc. | tratamento de anemia falciforme com um composto de ativação de piruvato cinase r |
| JP2023024954A (ja) * | 2021-08-09 | 2023-02-21 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ベータ－３アドレナリン作動性受容体に関連する障害の処置または予防に有用なベータ－３アドレナリン作動性受容体のモジュレーター |
| CA3230339A1 (en) * | 2021-08-26 | 2023-03-02 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor for the treatment or prevention of renal cystic disease and cardiorenal syndrome |
| WO2023057896A1 (en) * | 2021-10-06 | 2023-04-13 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
| WO2023154499A1 (en) * | 2022-02-14 | 2023-08-17 | Biogen Ma Inc. | Emopamil-binding protein inhibitors and uses thereof |
| CN114539103B (zh) * | 2022-03-21 | 2023-04-07 | 佳木斯黑龙农药有限公司 | 2-二氟乙氧基-6-三氟甲基苯磺酰氯的合成方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3028340A1 (de) * | 1980-07-25 | 1982-02-25 | Fa. Dr. Willmar Schwabe, 7500 Karlsruhe | Amino-desoxy-1.4;3.6-dianhydro-hexit-nitrate |
| US5254595A (en) | 1988-12-23 | 1993-10-19 | Elf Sanofi | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them |
| FR2751646B1 (fr) | 1996-07-23 | 1999-01-22 | Sanofi Sa | Phenoxypropanolamine a action antagoniste beta3-adrenergique |
| WO1998027080A1 (en) | 1996-12-19 | 1998-06-25 | Agrevo Uk Limited | Chromones useful as fungicides |
| FR2780057B1 (fr) * | 1998-06-18 | 2002-09-13 | Sanofi Sa | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| AU2525801A (en) * | 1999-12-17 | 2001-06-25 | Sanofi-Synthelabo | Phenoxypropanolamines, method for producing them and pharmaceutical compositionscontaining them |
| DE20204129U1 (de) | 2002-03-15 | 2002-07-25 | Wella Ag | Mittel zur Färbung von Keratinfasern mit Chinolinium-Farbstoffen |
| WO2005092860A1 (en) * | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds for the treatment of diseases |
| EP1833480A2 (en) * | 2004-11-30 | 2007-09-19 | Artesian Therapeutics, Inc. | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase |
| US8697674B2 (en) | 2004-12-29 | 2014-04-15 | Naturon, Inc. | Xanthurenic acid derivative pharmaceutical compositions and methods related thereto |
| WO2008094507A2 (en) | 2007-01-26 | 2008-08-07 | Cellicon Biotechnologies, Inc. | Novel fusion compounds |
| US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
| WO2009059225A2 (en) | 2007-11-02 | 2009-05-07 | Pain Therapeutics, Inc. | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin a |
| CA2779252C (en) | 2008-10-31 | 2015-05-05 | Pain Therapeutics, Inc. | Filamin a-binding anti-inflammatory analgesic |
| AU2009308702B2 (en) | 2008-10-31 | 2015-05-28 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
| US20100279997A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Analgesic that binds filamin a |
| WO2010058318A1 (en) * | 2008-11-21 | 2010-05-27 | Pfizer Inc. | 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors |
| US8785634B2 (en) * | 2010-04-26 | 2014-07-22 | Merck Sharp & Dohme Corp | Spiropiperidine prolylcarboxypeptidase inhibitors |
| EP2595483B1 (en) * | 2010-07-23 | 2017-03-22 | Merck Sharp & Dohme Corp. | Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
| JP2012092038A (ja) | 2010-10-26 | 2012-05-17 | F Hoffmann La Roche Ag | 糖尿病、糖尿病関連疾患又は糖尿病性合併症の予防又は治療剤 |
| JP6566867B2 (ja) | 2012-07-13 | 2019-08-28 | ペイン セラピューティクス インコーポレイテッド | 生きている患者でのアルツハイマー病アッセイ |
| DK2882428T3 (da) | 2012-07-13 | 2019-04-15 | Pain Therapeutics Inc | Fremgangsmåde til at inhibere tau-phosphorylering |
| GB201405359D0 (en) | 2014-03-25 | 2014-05-07 | Univ Liverpool | Synthetic process |
| MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| EP3720858B1 (en) * | 2017-12-06 | 2023-06-07 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto |
-
2017
- 2017-06-04 MA MA44037A patent/MA44037B1/fr unknown
- 2017-06-05 CR CR20180595A patent/CR20180595A/es unknown
- 2017-06-05 KR KR1020227004041A patent/KR102408272B1/ko active IP Right Grant
- 2017-06-05 EA EA201892817A patent/EA201892817A1/ru unknown
- 2017-06-05 IL IL289378A patent/IL289378B/en unknown
- 2017-06-05 AU AU2017278102A patent/AU2017278102B2/en active Active
- 2017-06-05 PT PT177306388T patent/PT3464292T/pt unknown
- 2017-06-05 MA MA045150A patent/MA45150A/fr unknown
- 2017-06-05 BR BR112018075201-0A patent/BR112018075201A2/pt active Search and Examination
- 2017-06-05 NZ NZ749202A patent/NZ749202A/en not_active IP Right Cessation
- 2017-06-05 CN CN201780047870.6A patent/CN109563103B/zh active Active
- 2017-06-05 DK DK17730638.8T patent/DK3464292T3/da active
- 2017-06-05 WO PCT/US2017/035867 patent/WO2017214002A1/en active Search and Examination
- 2017-06-05 TN TNP/2018/000391A patent/TN2018000391A1/en unknown
- 2017-06-05 US US16/307,830 patent/US20190284200A1/en not_active Abandoned
- 2017-06-05 EP EP17730638.8A patent/EP3464292B8/en active Active
- 2017-06-05 PE PE2018003180A patent/PE20190445A1/es unknown
- 2017-06-05 CA CA3026024A patent/CA3026024A1/en active Pending
- 2017-06-05 ES ES17730638T patent/ES2929737T3/es active Active
- 2017-06-05 UA UAA201900139A patent/UA125120C2/uk unknown
- 2017-06-05 KR KR1020197000005A patent/KR20190026731A/ko not_active IP Right Cessation
- 2017-06-05 MX MX2018015124A patent/MX2018015124A/es unknown
- 2017-06-05 SG SG11201810788QA patent/SG11201810788QA/en unknown
- 2017-06-05 JP JP2019516084A patent/JP6771246B2/ja active Active
- 2017-06-05 MY MYPI2018002257A patent/MY195982A/en unknown
- 2017-06-06 TW TW106118610A patent/TWI752963B/zh active
- 2017-06-06 AR ARP170101546A patent/AR108772A1/es active IP Right Grant
- 2017-06-06 TW TW110147004A patent/TWI784840B/zh active
-
2018
- 2018-11-20 IL IL263148A patent/IL263148B/en unknown
- 2018-12-03 PH PH12018502550A patent/PH12018502550A1/en unknown
- 2018-12-03 CL CL2018003451A patent/CL2018003451A1/es unknown
- 2018-12-05 MX MX2021014043A patent/MX2021014043A/es unknown
- 2018-12-05 NI NI201800130A patent/NI201800130A/es unknown
-
2019
- 2019-01-04 CO CONC2019/0000041A patent/CO2019000041A2/es unknown
- 2019-01-07 EC ECSENADI20191018A patent/ECSP19001018A/es unknown
- 2019-06-04 US US16/431,209 patent/US10479797B2/en active Active
- 2019-09-06 US US16/563,353 patent/US10662200B2/en active Active
-
2020
- 2020-05-12 US US16/872,812 patent/US10927123B2/en active Active
- 2020-09-18 JP JP2020157196A patent/JP7083087B2/ja active Active
- 2020-12-14 US US17/120,759 patent/US11560386B2/en active Active
-
2021
- 2021-07-20 AU AU2021206809A patent/AU2021206809B2/en active Active
-
2022
- 2022-04-21 JP JP2022069821A patent/JP7449329B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3464292T3 (da) | Modulatorer af beta-3-adrenerg receptor, der kan anvendes til behandling eller forebyggelse af lidelser relateret dertil | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3261640T3 (da) | 5ht-agonister til behandling af epilepsilidelser | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| DK3285803T3 (da) | Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine | |
| DK3227675T3 (da) | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3288577T3 (da) | Adiponectin-peptidomimetika til behandling af øjenlidelser | |
| DK3307299T3 (da) | Kombinationssammensætninger til behandling af lidelser krævende fjernelse eller ødelæggelse af uønskede celleformeringer | |
| DK3355889T3 (da) | Diaminopyrimidin-p2x3- og p2x2/3-receptormodulatorer til anvendelse i behandling af hoste | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3536324T3 (da) | 4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139 | |
| DK3388064T3 (da) | 2,4-thiazolidindionderivater i behandling af forstyrrelse i centralnervesystemet | |
| DK3233066T3 (da) | Orlistat- og acarbosepræparat med modificeret frigivelse til behand-ling af obesitas og relaterede metaboliske lidelser | |
| DK3217963T3 (da) | Fremgangsmåder til behandling af individer med prader-willis syndrom eller smith-magenis syndrom | |
| DK3978074T3 (da) | Terlipressin til behandling af hepatorenalt syndrom type 1 | |
| DK3439661T3 (da) | Fremgangsmåder til behandling af øjenlidelser | |
| DK3242888T3 (da) | Opløselige fgfr3-atrapper til behandling af skeletvækstforstyrrelser | |
| DK3512506T3 (da) | Anvendelse af pridopidin til behandling af retts syndrom | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| DK3442547T3 (da) | Lactobacillus reuteri MM4-1A til anvendelse i behandling eller forebyggelse af autismespektrumforstyrrelser |